Skip to Content


Sarah Karlin Smith, quoting Rachel Sachs
Politico
October 15, 2018

Read the full article

From the article:

A majority of voters tends to support the transparency move but remains skeptical of whether it will lead to lower drug costs. A July POLITICO/Harvard poll found 63 percent of Americans favored requiring drug advertisements to include pricing information, but only 28 percent believed it would bring lower costs. Health policy experts also say the pricing disclosure is unlikely to change the cost of drugs. “Transparency has not worked to decrease drug prices over the long term and there’s no reason to think it would work here,” said Rachel Sachs, a lawyer focused on health policy at Washington University in St. Louis.

Read more here!

Read the full article

Tags

fda   pharmaceuticals   rachel sachs   regulation